

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**KINGWORLD MEDICINES GROUP LIMITED**  
**金活醫藥集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code : 01110)

**ANNOUNCEMENT**  
**DELAY IN DESPATCH OF CIRCULAR IN RELATION TO**  
**MAJOR TRANSACTION**  
**MAIN CONTRACTOR CONSTRUCTION AGREEMENT**

Reference is made to the announcement (the “**Announcement**”) of Kingworld Medicines Group Limited (the “**Company**”) dated 25 June 2021 in relation to the Main Contractor Construction Agreement. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, a circular containing further details of the Agreement is expected to be despatched to the Shareholders on or before 19 July 2021.

As more time is required by the Company and the accountants of the Company to prepare the financial information of the Group and other information to be included in the circular under the Listing Rules, the Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a waiver from strict compliance with Rule 14.41(a) of the Listing Rules such that the circular is scheduled to be despatched to the Shareholders on or before 23 August 2021.

As at the date of this announcement, the Company has obtained a written shareholders’ approval from a closely allied group of Shareholders (being Golden Land, Golden Morning, Mr. Zhao and Ms. Chan). The circular is to be despatched to the Shareholders for information purposes only.

By order of the Board  
**Kingworld Medicines Group Limited**  
**Zhao Li Sheng**  
*Chairman*

Hong Kong, 12 July 2021

*As at the date of this announcement, the executive Directors are Mr. Zhao Li Sheng, Ms. Chan Lok San, and Mr. Zhou Xuhua, and the independent non-executive Directors are Mr. Duan Jidong, Mr. Zhang Jianbin and Mr. Wong Cheuk Lam.*